Ionis Pharmaceuticals, Inc.

Good morning and welcome to IONIS' fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walk, Senior Vice President of Investor Relations, to lead the call. Please begin.

Thank you, MJ. Before we begin, I encourage everyone to go to the investor section of the IONIS website To view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website that accompany today's call. With me on the call this morning are Brett Monia, our Chief Executive Officer, Kyle Genet, Chief Global Product Strategy Officer, Richard Geary, Chief Development Officer, and Beth Haugen, our Chief Financial Officer. And joining us for the Q&A portion of our call will be Eric Swayze, Executive Vice President of Research, and Eugene Schneider, Chief Clinical Development Officer. I would like to draw your attention to slide three, which contains our forward-looking language statement. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. And with that, I'll turn the call over to Brett.

Thanks, Wade. Good morning, everyone, and thank you for joining us on today's call. As we begin a new year, I am thrilled to share that Ionis has begun a new chapter as a fully integrated commercial stage biotechnology company with our first independent launch of Tringolza underway. With the FDA approval of Tringolza in late December, adults with familial chylomicronemius syndrome, or FCS, for the first time have access to a treatment that substantially and sustainably reduces triglyceride levels and substantially reduces the risk of life-threatening acute pancreatitis. Our highly experienced team has been executing the launch flawlessly, which enabled Tringolza to be in the hands of patients within a couple of weeks following the December 19th approval. And Tringolza is just the beginning. We're on track to deliver three additional independent launches over the next three years. Donald Dolorsen, a potential treatment, preferred treatment for hereditary angioedema later this year. A second indication for olizarcin and severe hypertriglyceridemia, or SHTG. A large patient population with high-end mutiny. And Zilgenersen for Alexander disease, a rare leukodystrophy with no approved therapies. These programs collectively provide the opportunity to help tens of thousands of patients and represent multi-billion dollar revenue potential. In addition to our independent launches, we also expect four launches from late-stage partner programs over the next three years. These important medicines are poised to treat a range of serious, life-threatening diseases, including several that target broad patient populations. Telecarsin for LP little a cardiovascular disease, addressing an independent cardiovascular disease risk factor with high admit need with no approved therapies. Eplontersin for ATTR cardiomyopathy, a progressive fatal condition that continues to be underdiagnosed with a significant need for more effective treatments. Bifiravirsin for chronic hepatitis B virus, a serious disease that affects hundreds of millions of people globally. And tefaxircin, previously referred to as Ionis FBLRX, in development for IgA nephropathy, one of the most common causes of chronic kidney disease and kidney failure. If approved, these important investigational medicines would join our other marketed partnered medicines, including Spinraza for SMA and Wenua for hereditary TTR polyneuropathy, which are generating considerable value for patients and revenue for Ionis. Our partnered medicines enable our innovative science to reach even more patients, bolster our strong revenue base, and provide substantial growth potential, while allowing us to focus our efforts on advancing the medicines we plan to commercialize. IONIS is on a path to bring important medicines to patients for years to come. And in turn, we are positioned to achieve substantial and sustained revenue growth and positive cash flow. Our recent accomplishments and ongoing investments position us well to drive accelerating value for all IONIS stakeholders. And with that, I'll turn the call over to Kyle.